{"disease": {"name": "Follicular lymphoma", "mondo_id": null, "ncit_id": null, "umls_id": null, "oncotree_code": "mixed"}, "updated_at": "2026-09-26", "genome_builds": ["hg19"], "cohort_count": 1, "cohort_count_status": "observed", "cohort_count_unit": "cohorts", "evaluable_patients": null, "evaluable_patients_status": "unknown", "evaluable_patients_unit": "patients", "alteration_types": ["SNV", "small indel", "amplification", "deep deletion"], "genes": [{"gene": "BCL2", "alteration_types": ["SNV / small indel", "amplification"], "altered": 67, "tested": 193, "frequency": 34.72, "cohort_count": 1, "frequency_range": {"min": 34.72, "max": 34.72}, "major_variants": ["A60V (n=6)", "A131V (n=6)", "G47D (n=5)", "P53S (n=5)", "A131D (n=3)"], "evidence_confidence": "low", "disease_relevance": "Curated target in the disease briefing.", "targetability": "Not an FDA-recognised biomarker of drug response as of November 2022. This is not a statement that the gene is undruggable: levels 2 to 4 and non-US approvals are outside this table.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry.", "FDA biomarker status is level 1 only, United States only, and frozen at November 2022; no badge does not mean not druggable."], "sources": [{"source_name": "cBioPortal · MSK-IMPACT Heme, follicular lymphoma subset (2022)", "source_url": "https://www.cbioportal.org/study/summary?id=heme_msk_impact_2022", "source_record_id": "heme_msk_impact_2022", "source_version": null, "retrieved_at": "2026-09-26", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: MSK-IMPACT Heme, follicular lymphoma subset (2022), 67/193 patients (34.72%).", "Observed in 1 of 1 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "heme_msk_impact_2022", "cohort_name": "MSK-IMPACT Heme, follicular lymphoma subset (2022)", "altered": 67, "tested": 193, "frequency": 34.72, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "213/2383", "coverage_note": null, "source_id": "heme_msk_impact_2022", "is_reference": true}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 100.0, "width": 1.0, "reference": 100.0, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 67, "tested": 193, "frequency": 34.72, "is_mutation": true}, "fda_badge": null, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "MS4A1", "alteration_types": [], "altered": null, "tested": null, "frequency": null, "cohort_count": 0, "frequency_range": {"min": null, "max": null}, "major_variants": [], "evidence_confidence": "low", "disease_relevance": "Curated target in the disease briefing.", "targetability": "Not an FDA-recognised biomarker of drug response as of November 2022. This is not a statement that the gene is undruggable: levels 2 to 4 and non-US approvals are outside this table.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry.", "FDA biomarker status is level 1 only, United States only, and frozen at November 2022; no badge does not mean not druggable."], "sources": [{"source_name": "cBioPortal · MSK-IMPACT Heme, follicular lymphoma subset (2022)", "source_url": "https://www.cbioportal.org/study/summary?id=heme_msk_impact_2022", "source_record_id": "heme_msk_impact_2022", "source_version": null, "retrieved_at": "2026-09-26", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Observed in 0 of 1 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "heme_msk_impact_2022", "cohort_name": "MSK-IMPACT Heme, follicular lymphoma subset (2022)", "altered": null, "tested": null, "frequency": null, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "not_assayed", "assayed": false, "assay_note": "Not on this cohort's gene panel.", "evaluable": false, "coverage": "213/2383", "coverage_note": null, "source_id": "heme_msk_impact_2022", "is_reference": true}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": null, "headline_alteration": {"kind": "SNV / small indel", "altered": 0, "tested": null, "frequency": 0.0, "is_mutation": true}, "fda_badge": null, "altered_status": "not_assayed", "altered_unit": "patients", "tested_status": "not_assayed", "tested_unit": "patients", "frequency_status": "not_assayed", "frequency_unit": "percent", "cohort_count_status": "not_observed", "cohort_count_unit": "cohorts"}, {"gene": "CD19", "alteration_types": [], "altered": null, "tested": null, "frequency": null, "cohort_count": 0, "frequency_range": {"min": null, "max": null}, "major_variants": [], "evidence_confidence": "low", "disease_relevance": "Curated target in the disease briefing.", "targetability": "Not an FDA-recognised biomarker of drug response as of November 2022. This is not a statement that the gene is undruggable: levels 2 to 4 and non-US approvals are outside this table.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry.", "FDA biomarker status is level 1 only, United States only, and frozen at November 2022; no badge does not mean not druggable."], "sources": [{"source_name": "cBioPortal · MSK-IMPACT Heme, follicular lymphoma subset (2022)", "source_url": "https://www.cbioportal.org/study/summary?id=heme_msk_impact_2022", "source_record_id": "heme_msk_impact_2022", "source_version": null, "retrieved_at": "2026-09-26", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Observed in 0 of 1 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "heme_msk_impact_2022", "cohort_name": "MSK-IMPACT Heme, follicular lymphoma subset (2022)", "altered": null, "tested": null, "frequency": null, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "not_assayed", "assayed": false, "assay_note": "Not on this cohort's gene panel.", "evaluable": false, "coverage": "213/2383", "coverage_note": null, "source_id": "heme_msk_impact_2022", "is_reference": true}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": null, "headline_alteration": {"kind": "SNV / small indel", "altered": 0, "tested": null, "frequency": 0.0, "is_mutation": true}, "fda_badge": null, "altered_status": "not_assayed", "altered_unit": "patients", "tested_status": "not_assayed", "tested_unit": "patients", "frequency_status": "not_assayed", "frequency_unit": "percent", "cohort_count_status": "not_observed", "cohort_count_unit": "cohorts"}, {"gene": "EZH2", "alteration_types": ["SNV / small indel"], "altered": 40, "tested": 193, "frequency": 20.73, "cohort_count": 1, "frequency_range": {"min": 20.73, "max": 20.73}, "major_variants": ["Y646F (n=14)", "Y646N (n=13)", "A692V (n=5)", "Y646H (n=4)", "A682G (n=3)"], "evidence_confidence": "low", "disease_relevance": "Curated target in the disease briefing.", "targetability": "FDA-recognised biomarker of drug response since 2020; 1 approved drug. Label alteration: A692V, Y646F, Y646C, Y646S, Y646N, Y646H, A682G.", "approved_drugs_other_diseases": ["Tazemetostat (Follicular lymphoma, 2020)"], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry.", "FDA biomarker status is level 1 only, United States only, and frozen at November 2022; no badge does not mean not druggable."], "sources": [{"source_name": "cBioPortal · MSK-IMPACT Heme, follicular lymphoma subset (2022)", "source_url": "https://www.cbioportal.org/study/summary?id=heme_msk_impact_2022", "source_record_id": "heme_msk_impact_2022", "source_version": null, "retrieved_at": "2026-09-26", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: MSK-IMPACT Heme, follicular lymphoma subset (2022), 40/193 patients (20.73%).", "Observed in 1 of 1 cohorts; frequencies are cohort-specific and not pooled.", "EZH2 is an FDA-recognised biomarker of drug response since 2020 (1 approved drug). Frequency here is not evidence that this patient population is eligible."], "cohort_frequencies": [{"cohort": "heme_msk_impact_2022", "cohort_name": "MSK-IMPACT Heme, follicular lymphoma subset (2022)", "altered": 40, "tested": 193, "frequency": 20.73, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "213/2383", "coverage_note": null, "source_id": "heme_msk_impact_2022", "is_reference": true}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 69.1, "width": 1.0, "reference": 69.1, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 40, "tested": 193, "frequency": 20.73, "is_mutation": true}, "fda_badge": {"gene": "EZH2", "label": "FDA biomarker", "title": "FDA-recognised biomarker since 2020 — first approval Tazemetostat (Follicular lymphoma, 2020). Alteration in the label: A692V, Y646F, Y646C, Y646S, Y646N, Y646H, A682G.", "agnostic": false, "negative_selection": false, "first_year": 2020, "alterations": ["A692V, Y646F, Y646C, Y646S, Y646N, Y646H, A682G"], "n_drugs": 1, "drugs": ["Tazemetostat (Follicular lymphoma, 2020)"], "hrr_group": false}, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "CREBBP", "alteration_types": ["SNV / small indel", "deep deletion"], "altered": 137, "tested": 193, "frequency": 70.98, "cohort_count": 1, "frequency_range": {"min": 70.98, "max": 70.98}, "major_variants": ["S1680del (n=20)", "R1446H (n=12)", "R1446C (n=10)", "D1435N (n=4)", "Y1503D (n=4)"], "evidence_confidence": "low", "disease_relevance": "Curated target in the disease briefing.", "targetability": "Not an FDA-recognised biomarker of drug response as of November 2022. This is not a statement that the gene is undruggable: levels 2 to 4 and non-US approvals are outside this table.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry.", "FDA biomarker status is level 1 only, United States only, and frozen at November 2022; no badge does not mean not druggable."], "sources": [{"source_name": "cBioPortal · MSK-IMPACT Heme, follicular lymphoma subset (2022)", "source_url": "https://www.cbioportal.org/study/summary?id=heme_msk_impact_2022", "source_record_id": "heme_msk_impact_2022", "source_version": null, "retrieved_at": "2026-09-26", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: MSK-IMPACT Heme, follicular lymphoma subset (2022), 137/193 patients (70.98%).", "Observed in 1 of 1 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "heme_msk_impact_2022", "cohort_name": "MSK-IMPACT Heme, follicular lymphoma subset (2022)", "altered": 137, "tested": 193, "frequency": 70.98, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "213/2383", "coverage_note": null, "source_id": "heme_msk_impact_2022", "is_reference": true}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 100.0, "width": 1.0, "reference": 100.0, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 137, "tested": 193, "frequency": 70.98, "is_mutation": true}, "fda_badge": null, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "KMT2D", "alteration_types": ["SNV / small indel", "deep deletion"], "altered": 128, "tested": 193, "frequency": 66.32, "cohort_count": 1, "frequency_range": {"min": 66.32, "max": 66.32}, "major_variants": ["S2910Rfs*32 (n=5)", "L1461Tfs*30 (n=3)", "Q4347Rfs*24 (n=3)", "L860Rfs*70 (n=3)", "X1303_splice (n=3)"], "evidence_confidence": "low", "disease_relevance": "Curated target in the disease briefing.", "targetability": "Not an FDA-recognised biomarker of drug response as of November 2022. This is not a statement that the gene is undruggable: levels 2 to 4 and non-US approvals are outside this table.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry.", "FDA biomarker status is level 1 only, United States only, and frozen at November 2022; no badge does not mean not druggable."], "sources": [{"source_name": "cBioPortal · MSK-IMPACT Heme, follicular lymphoma subset (2022)", "source_url": "https://www.cbioportal.org/study/summary?id=heme_msk_impact_2022", "source_record_id": "heme_msk_impact_2022", "source_version": null, "retrieved_at": "2026-09-26", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: MSK-IMPACT Heme, follicular lymphoma subset (2022), 128/193 patients (66.32%).", "Observed in 1 of 1 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "heme_msk_impact_2022", "cohort_name": "MSK-IMPACT Heme, follicular lymphoma subset (2022)", "altered": 128, "tested": 193, "frequency": 66.32, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "213/2383", "coverage_note": null, "source_id": "heme_msk_impact_2022", "is_reference": true}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 100.0, "width": 1.0, "reference": 100.0, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 128, "tested": 193, "frequency": 66.32, "is_mutation": true}, "fda_badge": null, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "CD79B", "alteration_types": ["SNV / small indel", "amplification"], "altered": 3, "tested": 193, "frequency": 1.55, "cohort_count": 1, "frequency_range": {"min": 1.55, "max": 1.55}, "major_variants": ["T205Sfs*6 (n=1)", "I175Mfs*28 (n=1)", "Y197D (n=1)"], "evidence_confidence": "low", "disease_relevance": "Curated target in the disease briefing.", "targetability": "Not an FDA-recognised biomarker of drug response as of November 2022. This is not a statement that the gene is undruggable: levels 2 to 4 and non-US approvals are outside this table.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry.", "FDA biomarker status is level 1 only, United States only, and frozen at November 2022; no badge does not mean not druggable."], "sources": [{"source_name": "cBioPortal · MSK-IMPACT Heme, follicular lymphoma subset (2022)", "source_url": "https://www.cbioportal.org/study/summary?id=heme_msk_impact_2022", "source_record_id": "heme_msk_impact_2022", "source_version": null, "retrieved_at": "2026-09-26", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: MSK-IMPACT Heme, follicular lymphoma subset (2022), 3/193 patients (1.55%).", "Observed in 1 of 1 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "heme_msk_impact_2022", "cohort_name": "MSK-IMPACT Heme, follicular lymphoma subset (2022)", "altered": 3, "tested": 193, "frequency": 1.55, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "213/2383", "coverage_note": null, "source_id": "heme_msk_impact_2022", "is_reference": true}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 5.17, "width": 1.0, "reference": 5.17, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 3, "tested": 193, "frequency": 1.55, "is_mutation": true}, "fda_badge": null, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "PIK3CD", "alteration_types": [], "altered": null, "tested": null, "frequency": null, "cohort_count": 0, "frequency_range": {"min": null, "max": null}, "major_variants": [], "evidence_confidence": "low", "disease_relevance": "Curated target in the disease briefing.", "targetability": "Not an FDA-recognised biomarker of drug response as of November 2022. This is not a statement that the gene is undruggable: levels 2 to 4 and non-US approvals are outside this table.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry.", "FDA biomarker status is level 1 only, United States only, and frozen at November 2022; no badge does not mean not druggable."], "sources": [{"source_name": "cBioPortal · MSK-IMPACT Heme, follicular lymphoma subset (2022)", "source_url": "https://www.cbioportal.org/study/summary?id=heme_msk_impact_2022", "source_record_id": "heme_msk_impact_2022", "source_version": null, "retrieved_at": "2026-09-26", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Observed in 0 of 1 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "heme_msk_impact_2022", "cohort_name": "MSK-IMPACT Heme, follicular lymphoma subset (2022)", "altered": null, "tested": null, "frequency": null, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "not_assayed", "assayed": false, "assay_note": "Not on this cohort's gene panel.", "evaluable": false, "coverage": "213/2383", "coverage_note": null, "source_id": "heme_msk_impact_2022", "is_reference": true}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": null, "headline_alteration": {"kind": "SNV / small indel", "altered": 0, "tested": null, "frequency": 0.0, "is_mutation": true}, "fda_badge": null, "altered_status": "not_assayed", "altered_unit": "patients", "tested_status": "not_assayed", "tested_unit": "patients", "frequency_status": "not_assayed", "frequency_unit": "percent", "cohort_count_status": "not_observed", "cohort_count_unit": "cohorts"}, {"gene": "BTK", "alteration_types": ["SNV / small indel"], "altered": 12, "tested": 193, "frequency": 6.22, "cohort_count": 1, "frequency_range": {"min": 6.22, "max": 6.22}, "major_variants": ["T316Sfs*6 (n=2)", "E301del (n=1)", "Y545D (n=1)", "G50D (n=1)", "R28G (n=1)"], "evidence_confidence": "low", "disease_relevance": "Curated target in the disease briefing.", "targetability": "Not an FDA-recognised biomarker of drug response as of November 2022. This is not a statement that the gene is undruggable: levels 2 to 4 and non-US approvals are outside this table.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry.", "FDA biomarker status is level 1 only, United States only, and frozen at November 2022; no badge does not mean not druggable."], "sources": [{"source_name": "cBioPortal · MSK-IMPACT Heme, follicular lymphoma subset (2022)", "source_url": "https://www.cbioportal.org/study/summary?id=heme_msk_impact_2022", "source_record_id": "heme_msk_impact_2022", "source_version": null, "retrieved_at": "2026-09-26", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: MSK-IMPACT Heme, follicular lymphoma subset (2022), 12/193 patients (6.22%).", "Observed in 1 of 1 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "heme_msk_impact_2022", "cohort_name": "MSK-IMPACT Heme, follicular lymphoma subset (2022)", "altered": 12, "tested": 193, "frequency": 6.22, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "213/2383", "coverage_note": null, "source_id": "heme_msk_impact_2022", "is_reference": true}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 20.73, "width": 1.0, "reference": 20.73, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 12, "tested": 193, "frequency": 6.22, "is_mutation": true}, "fda_badge": null, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "CD22", "alteration_types": [], "altered": null, "tested": null, "frequency": null, "cohort_count": 0, "frequency_range": {"min": null, "max": null}, "major_variants": [], "evidence_confidence": "low", "disease_relevance": "Curated target in the disease briefing.", "targetability": "Not an FDA-recognised biomarker of drug response as of November 2022. This is not a statement that the gene is undruggable: levels 2 to 4 and non-US approvals are outside this table.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry.", "FDA biomarker status is level 1 only, United States only, and frozen at November 2022; no badge does not mean not druggable."], "sources": [{"source_name": "cBioPortal · MSK-IMPACT Heme, follicular lymphoma subset (2022)", "source_url": "https://www.cbioportal.org/study/summary?id=heme_msk_impact_2022", "source_record_id": "heme_msk_impact_2022", "source_version": null, "retrieved_at": "2026-09-26", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Observed in 0 of 1 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "heme_msk_impact_2022", "cohort_name": "MSK-IMPACT Heme, follicular lymphoma subset (2022)", "altered": null, "tested": null, "frequency": null, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "not_assayed", "assayed": false, "assay_note": "Not on this cohort's gene panel.", "evaluable": false, "coverage": "213/2383", "coverage_note": null, "source_id": "heme_msk_impact_2022", "is_reference": true}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": null, "headline_alteration": {"kind": "SNV / small indel", "altered": 0, "tested": null, "frequency": 0.0, "is_mutation": true}, "fda_badge": null, "altered_status": "not_assayed", "altered_unit": "patients", "tested_status": "not_assayed", "tested_unit": "patients", "frequency_status": "not_assayed", "frequency_unit": "percent", "cohort_count_status": "not_observed", "cohort_count_unit": "cohorts"}, {"gene": "TNFRSF14", "alteration_types": ["SNV / small indel", "deep deletion"], "altered": 90, "tested": 193, "frequency": 46.63, "cohort_count": 1, "frequency_range": {"min": 46.63, "max": 46.63}, "major_variants": ["W12* (n=14)", "X102_splice (n=7)", "M1? (n=4)", "X23_splice (n=3)", "G60D (n=3)"], "evidence_confidence": "low", "disease_relevance": "Curated target in the disease briefing.", "targetability": "Not an FDA-recognised biomarker of drug response as of November 2022. This is not a statement that the gene is undruggable: levels 2 to 4 and non-US approvals are outside this table.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry.", "FDA biomarker status is level 1 only, United States only, and frozen at November 2022; no badge does not mean not druggable."], "sources": [{"source_name": "cBioPortal · MSK-IMPACT Heme, follicular lymphoma subset (2022)", "source_url": "https://www.cbioportal.org/study/summary?id=heme_msk_impact_2022", "source_record_id": "heme_msk_impact_2022", "source_version": null, "retrieved_at": "2026-09-26", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: MSK-IMPACT Heme, follicular lymphoma subset (2022), 90/193 patients (46.63%).", "Observed in 1 of 1 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "heme_msk_impact_2022", "cohort_name": "MSK-IMPACT Heme, follicular lymphoma subset (2022)", "altered": 90, "tested": 193, "frequency": 46.63, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "213/2383", "coverage_note": null, "source_id": "heme_msk_impact_2022", "is_reference": true}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 100.0, "width": 1.0, "reference": 100.0, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 90, "tested": 193, "frequency": 46.63, "is_mutation": true}, "fda_badge": null, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "STAT6", "alteration_types": ["SNV / small indel", "amplification"], "altered": 39, "tested": 193, "frequency": 20.21, "cohort_count": 1, "frequency_range": {"min": 20.21, "max": 20.21}, "major_variants": ["D419G (n=13)", "E377K (n=6)", "D419N (n=5)", "D419H (n=4)", "E372K (n=3)"], "evidence_confidence": "low", "disease_relevance": "Curated target in the disease briefing.", "targetability": "Not an FDA-recognised biomarker of drug response as of November 2022. This is not a statement that the gene is undruggable: levels 2 to 4 and non-US approvals are outside this table.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry.", "FDA biomarker status is level 1 only, United States only, and frozen at November 2022; no badge does not mean not druggable."], "sources": [{"source_name": "cBioPortal · MSK-IMPACT Heme, follicular lymphoma subset (2022)", "source_url": "https://www.cbioportal.org/study/summary?id=heme_msk_impact_2022", "source_record_id": "heme_msk_impact_2022", "source_version": null, "retrieved_at": "2026-09-26", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: MSK-IMPACT Heme, follicular lymphoma subset (2022), 39/193 patients (20.21%).", "Observed in 1 of 1 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "heme_msk_impact_2022", "cohort_name": "MSK-IMPACT Heme, follicular lymphoma subset (2022)", "altered": 39, "tested": 193, "frequency": 20.21, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "213/2383", "coverage_note": null, "source_id": "heme_msk_impact_2022", "is_reference": true}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 67.37, "width": 1.0, "reference": 67.37, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 39, "tested": 193, "frequency": 20.21, "is_mutation": true}, "fda_badge": null, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "FOXO1", "alteration_types": ["SNV / small indel", "deep deletion"], "altered": 35, "tested": 193, "frequency": 18.13, "cohort_count": 1, "frequency_range": {"min": 18.13, "max": 18.13}, "major_variants": ["T24I (n=7)", "S22P (n=6)", "M1? (n=6)", "T24A (n=6)", "S152R (n=4)"], "evidence_confidence": "low", "disease_relevance": "Among the most frequently mutated genes in the reference cohort.", "targetability": "Not an FDA-recognised biomarker of drug response as of November 2022. This is not a statement that the gene is undruggable: levels 2 to 4 and non-US approvals are outside this table.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry.", "FDA biomarker status is level 1 only, United States only, and frozen at November 2022; no badge does not mean not druggable."], "sources": [{"source_name": "cBioPortal · MSK-IMPACT Heme, follicular lymphoma subset (2022)", "source_url": "https://www.cbioportal.org/study/summary?id=heme_msk_impact_2022", "source_record_id": "heme_msk_impact_2022", "source_version": null, "retrieved_at": "2026-09-26", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: MSK-IMPACT Heme, follicular lymphoma subset (2022), 35/193 patients (18.13%).", "Observed in 1 of 1 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "heme_msk_impact_2022", "cohort_name": "MSK-IMPACT Heme, follicular lymphoma subset (2022)", "altered": 35, "tested": 193, "frequency": 18.13, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "213/2383", "coverage_note": null, "source_id": "heme_msk_impact_2022", "is_reference": true}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 60.43, "width": 1.0, "reference": 60.43, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 35, "tested": 193, "frequency": 18.13, "is_mutation": true}, "fda_badge": null, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "SOCS1", "alteration_types": ["SNV / small indel", "deep deletion"], "altered": 30, "tested": 193, "frequency": 15.54, "cohort_count": 1, "frequency_range": {"min": 15.54, "max": 15.54}, "major_variants": ["M161_L162delinsKV (n=2)", "S116N (n=2)", "A17T (n=2)", "I126L (n=1)", "L73R (n=1)"], "evidence_confidence": "low", "disease_relevance": "Among the most frequently mutated genes in the reference cohort.", "targetability": "Not an FDA-recognised biomarker of drug response as of November 2022. This is not a statement that the gene is undruggable: levels 2 to 4 and non-US approvals are outside this table.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry.", "FDA biomarker status is level 1 only, United States only, and frozen at November 2022; no badge does not mean not druggable."], "sources": [{"source_name": "cBioPortal · MSK-IMPACT Heme, follicular lymphoma subset (2022)", "source_url": "https://www.cbioportal.org/study/summary?id=heme_msk_impact_2022", "source_record_id": "heme_msk_impact_2022", "source_version": null, "retrieved_at": "2026-09-26", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: MSK-IMPACT Heme, follicular lymphoma subset (2022), 30/193 patients (15.54%).", "Observed in 1 of 1 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "heme_msk_impact_2022", "cohort_name": "MSK-IMPACT Heme, follicular lymphoma subset (2022)", "altered": 30, "tested": 193, "frequency": 15.54, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "213/2383", "coverage_note": null, "source_id": "heme_msk_impact_2022", "is_reference": true}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 51.8, "width": 1.0, "reference": 51.8, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 30, "tested": 193, "frequency": 15.54, "is_mutation": true}, "fda_badge": null, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "H1-4", "alteration_types": ["SNV / small indel"], "altered": 30, "tested": 193, "frequency": 15.54, "cohort_count": 1, "frequency_range": {"min": 15.54, "max": 15.54}, "major_variants": ["A167V (n=3)", "A170V (n=2)", "A123T (n=2)", "A116V (n=2)", "A65P (n=2)"], "evidence_confidence": "low", "disease_relevance": "Among the most frequently mutated genes in the reference cohort.", "targetability": "Not an FDA-recognised biomarker of drug response as of November 2022. This is not a statement that the gene is undruggable: levels 2 to 4 and non-US approvals are outside this table.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry.", "FDA biomarker status is level 1 only, United States only, and frozen at November 2022; no badge does not mean not druggable."], "sources": [{"source_name": "cBioPortal · MSK-IMPACT Heme, follicular lymphoma subset (2022)", "source_url": "https://www.cbioportal.org/study/summary?id=heme_msk_impact_2022", "source_record_id": "heme_msk_impact_2022", "source_version": null, "retrieved_at": "2026-09-26", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: MSK-IMPACT Heme, follicular lymphoma subset (2022), 30/193 patients (15.54%).", "Observed in 1 of 1 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "heme_msk_impact_2022", "cohort_name": "MSK-IMPACT Heme, follicular lymphoma subset (2022)", "altered": 30, "tested": 193, "frequency": 15.54, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "213/2383", "coverage_note": null, "source_id": "heme_msk_impact_2022", "is_reference": true}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 51.8, "width": 1.0, "reference": 51.8, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 30, "tested": 193, "frequency": 15.54, "is_mutation": true}, "fda_badge": null, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "IRF8", "alteration_types": ["SNV / small indel"], "altered": 29, "tested": 193, "frequency": 15.03, "cohort_count": 1, "frequency_range": {"min": 15.03, "max": 15.03}, "major_variants": ["S55A (n=3)", "T80A (n=3)", "Y23H (n=3)", "Q392* (n=2)", "V426D (n=2)"], "evidence_confidence": "low", "disease_relevance": "Among the most frequently mutated genes in the reference cohort.", "targetability": "Not an FDA-recognised biomarker of drug response as of November 2022. This is not a statement that the gene is undruggable: levels 2 to 4 and non-US approvals are outside this table.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry.", "FDA biomarker status is level 1 only, United States only, and frozen at November 2022; no badge does not mean not druggable."], "sources": [{"source_name": "cBioPortal · MSK-IMPACT Heme, follicular lymphoma subset (2022)", "source_url": "https://www.cbioportal.org/study/summary?id=heme_msk_impact_2022", "source_record_id": "heme_msk_impact_2022", "source_version": null, "retrieved_at": "2026-09-26", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: MSK-IMPACT Heme, follicular lymphoma subset (2022), 29/193 patients (15.03%).", "Observed in 1 of 1 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "heme_msk_impact_2022", "cohort_name": "MSK-IMPACT Heme, follicular lymphoma subset (2022)", "altered": 29, "tested": 193, "frequency": 15.03, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "213/2383", "coverage_note": null, "source_id": "heme_msk_impact_2022", "is_reference": true}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 50.1, "width": 1.0, "reference": 50.1, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 29, "tested": 193, "frequency": 15.03, "is_mutation": true}, "fda_badge": null, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "ARID1A", "alteration_types": ["SNV / small indel"], "altered": 26, "tested": 193, "frequency": 13.47, "cohort_count": 1, "frequency_range": {"min": 13.47, "max": 13.47}, "major_variants": ["Y195Cfs*48 (n=2)", "G1137* (n=2)", "G105Efs*8 (n=2)", "Q520* (n=1)", "S1961Rfs*53 (n=1)"], "evidence_confidence": "low", "disease_relevance": "Among the most frequently mutated genes in the reference cohort.", "targetability": "Not an FDA-recognised biomarker of drug response as of November 2022. This is not a statement that the gene is undruggable: levels 2 to 4 and non-US approvals are outside this table.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry.", "FDA biomarker status is level 1 only, United States only, and frozen at November 2022; no badge does not mean not druggable."], "sources": [{"source_name": "cBioPortal · MSK-IMPACT Heme, follicular lymphoma subset (2022)", "source_url": "https://www.cbioportal.org/study/summary?id=heme_msk_impact_2022", "source_record_id": "heme_msk_impact_2022", "source_version": null, "retrieved_at": "2026-09-26", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: MSK-IMPACT Heme, follicular lymphoma subset (2022), 26/193 patients (13.47%).", "Observed in 1 of 1 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "heme_msk_impact_2022", "cohort_name": "MSK-IMPACT Heme, follicular lymphoma subset (2022)", "altered": 26, "tested": 193, "frequency": 13.47, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "213/2383", "coverage_note": null, "source_id": "heme_msk_impact_2022", "is_reference": true}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 44.9, "width": 1.0, "reference": 44.9, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 26, "tested": 193, "frequency": 13.47, "is_mutation": true}, "fda_badge": null, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "MEF2B", "alteration_types": ["SNV / small indel"], "altered": 23, "tested": 193, "frequency": 11.92, "cohort_count": 1, "frequency_range": {"min": 11.92, "max": 11.92}, "major_variants": ["D83V (n=5)", "D83A (n=4)", "R24Q (n=3)", "T70R (n=3)", "Y69H (n=2)"], "evidence_confidence": "low", "disease_relevance": "Among the most frequently mutated genes in the reference cohort.", "targetability": "Not an FDA-recognised biomarker of drug response as of November 2022. This is not a statement that the gene is undruggable: levels 2 to 4 and non-US approvals are outside this table.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry.", "FDA biomarker status is level 1 only, United States only, and frozen at November 2022; no badge does not mean not druggable."], "sources": [{"source_name": "cBioPortal · MSK-IMPACT Heme, follicular lymphoma subset (2022)", "source_url": "https://www.cbioportal.org/study/summary?id=heme_msk_impact_2022", "source_record_id": "heme_msk_impact_2022", "source_version": null, "retrieved_at": "2026-09-26", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: MSK-IMPACT Heme, follicular lymphoma subset (2022), 23/193 patients (11.92%).", "Observed in 1 of 1 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "heme_msk_impact_2022", "cohort_name": "MSK-IMPACT Heme, follicular lymphoma subset (2022)", "altered": 23, "tested": 193, "frequency": 11.92, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "213/2383", "coverage_note": null, "source_id": "heme_msk_impact_2022", "is_reference": true}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 39.73, "width": 1.0, "reference": 39.73, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 23, "tested": 193, "frequency": 11.92, "is_mutation": true}, "fda_badge": null, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "EP300", "alteration_types": ["SNV / small indel"], "altered": 21, "tested": 193, "frequency": 10.88, "cohort_count": 1, "frequency_range": {"min": 10.88, "max": 10.88}, "major_variants": ["Y1467D (n=3)", "Y1467F (n=3)", "Y1467N (n=2)", "G1375R (n=2)", "Y1446N (n=2)"], "evidence_confidence": "low", "disease_relevance": "Among the most frequently mutated genes in the reference cohort.", "targetability": "Not an FDA-recognised biomarker of drug response as of November 2022. This is not a statement that the gene is undruggable: levels 2 to 4 and non-US approvals are outside this table.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry.", "FDA biomarker status is level 1 only, United States only, and frozen at November 2022; no badge does not mean not druggable."], "sources": [{"source_name": "cBioPortal · MSK-IMPACT Heme, follicular lymphoma subset (2022)", "source_url": "https://www.cbioportal.org/study/summary?id=heme_msk_impact_2022", "source_record_id": "heme_msk_impact_2022", "source_version": null, "retrieved_at": "2026-09-26", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: MSK-IMPACT Heme, follicular lymphoma subset (2022), 21/193 patients (10.88%).", "Observed in 1 of 1 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "heme_msk_impact_2022", "cohort_name": "MSK-IMPACT Heme, follicular lymphoma subset (2022)", "altered": 21, "tested": 193, "frequency": 10.88, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "213/2383", "coverage_note": null, "source_id": "heme_msk_impact_2022", "is_reference": true}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 36.27, "width": 1.0, "reference": 36.27, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 21, "tested": 193, "frequency": 10.88, "is_mutation": true}, "fda_badge": null, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "CARD11", "alteration_types": ["SNV / small indel", "amplification"], "altered": 21, "tested": 193, "frequency": 10.88, "cohort_count": 1, "frequency_range": {"min": 10.88, "max": 10.88}, "major_variants": ["D357V (n=5)", "L253P (n=2)", "S250P (n=2)", "Q249P (n=2)", "E134G (n=1)"], "evidence_confidence": "low", "disease_relevance": "Among the most frequently mutated genes in the reference cohort.", "targetability": "Not an FDA-recognised biomarker of drug response as of November 2022. This is not a statement that the gene is undruggable: levels 2 to 4 and non-US approvals are outside this table.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry.", "FDA biomarker status is level 1 only, United States only, and frozen at November 2022; no badge does not mean not druggable."], "sources": [{"source_name": "cBioPortal · MSK-IMPACT Heme, follicular lymphoma subset (2022)", "source_url": "https://www.cbioportal.org/study/summary?id=heme_msk_impact_2022", "source_record_id": "heme_msk_impact_2022", "source_version": null, "retrieved_at": "2026-09-26", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: MSK-IMPACT Heme, follicular lymphoma subset (2022), 21/193 patients (10.88%).", "Observed in 1 of 1 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "heme_msk_impact_2022", "cohort_name": "MSK-IMPACT Heme, follicular lymphoma subset (2022)", "altered": 21, "tested": 193, "frequency": 10.88, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "213/2383", "coverage_note": null, "source_id": "heme_msk_impact_2022", "is_reference": true}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 36.27, "width": 1.0, "reference": 36.27, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 21, "tested": 193, "frequency": 10.88, "is_mutation": true}, "fda_badge": null, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "TNFAIP3", "alteration_types": ["SNV / small indel", "deep deletion"], "altered": 20, "tested": 193, "frequency": 10.36, "cohort_count": 1, "frequency_range": {"min": 10.36, "max": 10.36}, "major_variants": ["L324Qfs*7 (n=3)", "V398Efs*8 (n=2)", "K96Sfs*14 (n=2)", "X269_splice (n=2)", "R136Qfs*3 (n=2)"], "evidence_confidence": "low", "disease_relevance": "Among the most frequently mutated genes in the reference cohort.", "targetability": "Not an FDA-recognised biomarker of drug response as of November 2022. This is not a statement that the gene is undruggable: levels 2 to 4 and non-US approvals are outside this table.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry.", "FDA biomarker status is level 1 only, United States only, and frozen at November 2022; no badge does not mean not druggable."], "sources": [{"source_name": "cBioPortal · MSK-IMPACT Heme, follicular lymphoma subset (2022)", "source_url": "https://www.cbioportal.org/study/summary?id=heme_msk_impact_2022", "source_record_id": "heme_msk_impact_2022", "source_version": null, "retrieved_at": "2026-09-26", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: MSK-IMPACT Heme, follicular lymphoma subset (2022), 20/193 patients (10.36%).", "Observed in 1 of 1 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "heme_msk_impact_2022", "cohort_name": "MSK-IMPACT Heme, follicular lymphoma subset (2022)", "altered": 20, "tested": 193, "frequency": 10.36, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "213/2383", "coverage_note": null, "source_id": "heme_msk_impact_2022", "is_reference": true}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 34.53, "width": 1.0, "reference": 34.53, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 20, "tested": 193, "frequency": 10.36, "is_mutation": true}, "fda_badge": null, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "GNA13", "alteration_types": ["SNV / small indel"], "altered": 19, "tested": 193, "frequency": 9.84, "cohort_count": 1, "frequency_range": {"min": 9.84, "max": 9.84}, "major_variants": ["V98E (n=3)", "E33D (n=2)", "M1? (n=2)", "K94E (n=1)", "Q67L (n=1)"], "evidence_confidence": "low", "disease_relevance": "Among the most frequently mutated genes in the reference cohort.", "targetability": "Not an FDA-recognised biomarker of drug response as of November 2022. This is not a statement that the gene is undruggable: levels 2 to 4 and non-US approvals are outside this table.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry.", "FDA biomarker status is level 1 only, United States only, and frozen at November 2022; no badge does not mean not druggable."], "sources": [{"source_name": "cBioPortal · MSK-IMPACT Heme, follicular lymphoma subset (2022)", "source_url": "https://www.cbioportal.org/study/summary?id=heme_msk_impact_2022", "source_record_id": "heme_msk_impact_2022", "source_version": null, "retrieved_at": "2026-09-26", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: MSK-IMPACT Heme, follicular lymphoma subset (2022), 19/193 patients (9.84%).", "Observed in 1 of 1 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "heme_msk_impact_2022", "cohort_name": "MSK-IMPACT Heme, follicular lymphoma subset (2022)", "altered": 19, "tested": 193, "frequency": 9.84, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "213/2383", "coverage_note": null, "source_id": "heme_msk_impact_2022", "is_reference": true}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 32.8, "width": 1.0, "reference": 32.8, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 19, "tested": 193, "frequency": 9.84, "is_mutation": true}, "fda_badge": null, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "TP53", "alteration_types": ["SNV / small indel"], "altered": 18, "tested": 193, "frequency": 9.33, "cohort_count": 1, "frequency_range": {"min": 9.33, "max": 9.33}, "major_variants": ["Y234D (n=2)", "R175H (n=2)", "R249G (n=1)", "V274A (n=1)", "R282W (n=1)"], "evidence_confidence": "low", "disease_relevance": "Among the most frequently mutated genes in the reference cohort.", "targetability": "Not an FDA-recognised biomarker of drug response as of November 2022. This is not a statement that the gene is undruggable: levels 2 to 4 and non-US approvals are outside this table.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry.", "FDA biomarker status is level 1 only, United States only, and frozen at November 2022; no badge does not mean not druggable."], "sources": [{"source_name": "cBioPortal · MSK-IMPACT Heme, follicular lymphoma subset (2022)", "source_url": "https://www.cbioportal.org/study/summary?id=heme_msk_impact_2022", "source_record_id": "heme_msk_impact_2022", "source_version": null, "retrieved_at": "2026-09-26", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: MSK-IMPACT Heme, follicular lymphoma subset (2022), 18/193 patients (9.33%).", "Observed in 1 of 1 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "heme_msk_impact_2022", "cohort_name": "MSK-IMPACT Heme, follicular lymphoma subset (2022)", "altered": 18, "tested": 193, "frequency": 9.33, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "213/2383", "coverage_note": null, "source_id": "heme_msk_impact_2022", "is_reference": true}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 31.1, "width": 1.0, "reference": 31.1, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 18, "tested": 193, "frequency": 9.33, "is_mutation": true}, "fda_badge": null, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "RRAGC", "alteration_types": ["SNV / small indel"], "altered": 18, "tested": 193, "frequency": 9.33, "cohort_count": 1, "frequency_range": {"min": 9.33, "max": 9.33}, "major_variants": ["P87L (n=3)", "G119R (n=3)", "T90N (n=3)", "S75F (n=1)", "D116H (n=1)"], "evidence_confidence": "low", "disease_relevance": "Among the most frequently mutated genes in the reference cohort.", "targetability": "Not an FDA-recognised biomarker of drug response as of November 2022. This is not a statement that the gene is undruggable: levels 2 to 4 and non-US approvals are outside this table.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry.", "FDA biomarker status is level 1 only, United States only, and frozen at November 2022; no badge does not mean not druggable."], "sources": [{"source_name": "cBioPortal · MSK-IMPACT Heme, follicular lymphoma subset (2022)", "source_url": "https://www.cbioportal.org/study/summary?id=heme_msk_impact_2022", "source_record_id": "heme_msk_impact_2022", "source_version": null, "retrieved_at": "2026-09-26", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: MSK-IMPACT Heme, follicular lymphoma subset (2022), 18/193 patients (9.33%).", "Observed in 1 of 1 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "heme_msk_impact_2022", "cohort_name": "MSK-IMPACT Heme, follicular lymphoma subset (2022)", "altered": 18, "tested": 193, "frequency": 9.33, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "213/2383", "coverage_note": null, "source_id": "heme_msk_impact_2022", "is_reference": true}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 31.1, "width": 1.0, "reference": 31.1, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 18, "tested": 193, "frequency": 9.33, "is_mutation": true}, "fda_badge": null, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "ATP6V1B2", "alteration_types": ["SNV / small indel"], "altered": 16, "tested": 193, "frequency": 8.29, "cohort_count": 1, "frequency_range": {"min": 8.29, "max": 8.29}, "major_variants": ["R400Q (n=13)", "Y371C (n=2)", "M234T (n=1)", "T411I (n=1)", "T49A (n=1)"], "evidence_confidence": "low", "disease_relevance": "Among the most frequently mutated genes in the reference cohort.", "targetability": "Not an FDA-recognised biomarker of drug response as of November 2022. This is not a statement that the gene is undruggable: levels 2 to 4 and non-US approvals are outside this table.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry.", "FDA biomarker status is level 1 only, United States only, and frozen at November 2022; no badge does not mean not druggable."], "sources": [{"source_name": "cBioPortal · MSK-IMPACT Heme, follicular lymphoma subset (2022)", "source_url": "https://www.cbioportal.org/study/summary?id=heme_msk_impact_2022", "source_record_id": "heme_msk_impact_2022", "source_version": null, "retrieved_at": "2026-09-26", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: MSK-IMPACT Heme, follicular lymphoma subset (2022), 16/193 patients (8.29%).", "Observed in 1 of 1 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "heme_msk_impact_2022", "cohort_name": "MSK-IMPACT Heme, follicular lymphoma subset (2022)", "altered": 16, "tested": 193, "frequency": 8.29, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "213/2383", "coverage_note": null, "source_id": "heme_msk_impact_2022", "is_reference": true}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 27.63, "width": 1.0, "reference": 27.63, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 16, "tested": 193, "frequency": 8.29, "is_mutation": true}, "fda_badge": null, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "BCR", "alteration_types": ["SNV / small indel"], "altered": 15, "tested": 193, "frequency": 7.77, "cohort_count": 1, "frequency_range": {"min": 7.77, "max": 7.77}, "major_variants": ["P20S (n=2)", "G6D (n=2)", "G124D (n=1)", "P113S (n=1)", "E141K (n=1)"], "evidence_confidence": "low", "disease_relevance": "Among the most frequently mutated genes in the reference cohort.", "targetability": "Not an FDA-recognised biomarker of drug response as of November 2022. This is not a statement that the gene is undruggable: levels 2 to 4 and non-US approvals are outside this table.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry.", "FDA biomarker status is level 1 only, United States only, and frozen at November 2022; no badge does not mean not druggable."], "sources": [{"source_name": "cBioPortal · MSK-IMPACT Heme, follicular lymphoma subset (2022)", "source_url": "https://www.cbioportal.org/study/summary?id=heme_msk_impact_2022", "source_record_id": "heme_msk_impact_2022", "source_version": null, "retrieved_at": "2026-09-26", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: MSK-IMPACT Heme, follicular lymphoma subset (2022), 15/193 patients (7.77%).", "Observed in 1 of 1 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "heme_msk_impact_2022", "cohort_name": "MSK-IMPACT Heme, follicular lymphoma subset (2022)", "altered": 15, "tested": 193, "frequency": 7.77, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "213/2383", "coverage_note": null, "source_id": "heme_msk_impact_2022", "is_reference": true}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 25.9, "width": 1.0, "reference": 25.9, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 15, "tested": 193, "frequency": 7.77, "is_mutation": true}, "fda_badge": null, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "SGK1", "alteration_types": ["SNV / small indel", "deep deletion"], "altered": 14, "tested": 193, "frequency": 7.25, "cohort_count": 1, "frequency_range": {"min": 7.25, "max": 7.25}, "major_variants": ["X51_splice (n=3)", "A48V (n=2)", "X26_splice (n=1)", "G259V (n=1)", "F38* (n=1)"], "evidence_confidence": "low", "disease_relevance": "Among the most frequently mutated genes in the reference cohort.", "targetability": "Not an FDA-recognised biomarker of drug response as of November 2022. This is not a statement that the gene is undruggable: levels 2 to 4 and non-US approvals are outside this table.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry.", "FDA biomarker status is level 1 only, United States only, and frozen at November 2022; no badge does not mean not druggable."], "sources": [{"source_name": "cBioPortal · MSK-IMPACT Heme, follicular lymphoma subset (2022)", "source_url": "https://www.cbioportal.org/study/summary?id=heme_msk_impact_2022", "source_record_id": "heme_msk_impact_2022", "source_version": null, "retrieved_at": "2026-09-26", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: MSK-IMPACT Heme, follicular lymphoma subset (2022), 14/193 patients (7.25%).", "Observed in 1 of 1 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "heme_msk_impact_2022", "cohort_name": "MSK-IMPACT Heme, follicular lymphoma subset (2022)", "altered": 14, "tested": 193, "frequency": 7.25, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "213/2383", "coverage_note": null, "source_id": "heme_msk_impact_2022", "is_reference": true}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 24.17, "width": 1.0, "reference": 24.17, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 14, "tested": 193, "frequency": 7.25, "is_mutation": true}, "fda_badge": null, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "PIM1", "alteration_types": ["SNV / small indel", "amplification"], "altered": 14, "tested": 193, "frequency": 7.25, "cohort_count": 1, "frequency_range": {"min": 7.25, "max": 7.25}, "major_variants": ["S75P (n=2)", "L80Rfs*7 (n=1)", "X35_splice (n=1)", "G28V (n=1)", "L25V (n=1)"], "evidence_confidence": "low", "disease_relevance": "Among the most frequently mutated genes in the reference cohort.", "targetability": "Not an FDA-recognised biomarker of drug response as of November 2022. This is not a statement that the gene is undruggable: levels 2 to 4 and non-US approvals are outside this table.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry.", "FDA biomarker status is level 1 only, United States only, and frozen at November 2022; no badge does not mean not druggable."], "sources": [{"source_name": "cBioPortal · MSK-IMPACT Heme, follicular lymphoma subset (2022)", "source_url": "https://www.cbioportal.org/study/summary?id=heme_msk_impact_2022", "source_record_id": "heme_msk_impact_2022", "source_version": null, "retrieved_at": "2026-09-26", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: MSK-IMPACT Heme, follicular lymphoma subset (2022), 14/193 patients (7.25%).", "Observed in 1 of 1 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "heme_msk_impact_2022", "cohort_name": "MSK-IMPACT Heme, follicular lymphoma subset (2022)", "altered": 14, "tested": 193, "frequency": 7.25, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "213/2383", "coverage_note": null, "source_id": "heme_msk_impact_2022", "is_reference": true}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 24.17, "width": 1.0, "reference": 24.17, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 14, "tested": 193, "frequency": 7.25, "is_mutation": true}, "fda_badge": null, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "SRSF2", "alteration_types": ["SNV / small indel"], "altered": 13, "tested": 193, "frequency": 6.74, "cohort_count": 1, "frequency_range": {"min": 6.74, "max": 6.74}, "major_variants": ["P95R (n=3)", "P95_R117del (n=2)", "G93_H100del (n=1)", "P95L (n=1)", "Y92N (n=1)"], "evidence_confidence": "low", "disease_relevance": "Among the most frequently mutated genes in the reference cohort.", "targetability": "Not an FDA-recognised biomarker of drug response as of November 2022. This is not a statement that the gene is undruggable: levels 2 to 4 and non-US approvals are outside this table.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry.", "FDA biomarker status is level 1 only, United States only, and frozen at November 2022; no badge does not mean not druggable."], "sources": [{"source_name": "cBioPortal · MSK-IMPACT Heme, follicular lymphoma subset (2022)", "source_url": "https://www.cbioportal.org/study/summary?id=heme_msk_impact_2022", "source_record_id": "heme_msk_impact_2022", "source_version": null, "retrieved_at": "2026-09-26", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: MSK-IMPACT Heme, follicular lymphoma subset (2022), 13/193 patients (6.74%).", "Observed in 1 of 1 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "heme_msk_impact_2022", "cohort_name": "MSK-IMPACT Heme, follicular lymphoma subset (2022)", "altered": 13, "tested": 193, "frequency": 6.74, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "213/2383", "coverage_note": null, "source_id": "heme_msk_impact_2022", "is_reference": true}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 22.47, "width": 1.0, "reference": 22.47, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 13, "tested": 193, "frequency": 6.74, "is_mutation": true}, "fda_badge": null, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "SETD1B", "alteration_types": ["SNV / small indel", "deep deletion"], "altered": 13, "tested": 193, "frequency": 6.74, "cohort_count": 1, "frequency_range": {"min": 6.74, "max": 6.74}, "major_variants": ["H8Pfs*30 (n=4)", "P452Hfs*57 (n=2)", "K91N (n=1)", "L1532Ffs*35 (n=1)", "S1814N (n=1)"], "evidence_confidence": "low", "disease_relevance": "Among the most frequently mutated genes in the reference cohort.", "targetability": "Not an FDA-recognised biomarker of drug response as of November 2022. This is not a statement that the gene is undruggable: levels 2 to 4 and non-US approvals are outside this table.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry.", "FDA biomarker status is level 1 only, United States only, and frozen at November 2022; no badge does not mean not druggable."], "sources": [{"source_name": "cBioPortal · MSK-IMPACT Heme, follicular lymphoma subset (2022)", "source_url": "https://www.cbioportal.org/study/summary?id=heme_msk_impact_2022", "source_record_id": "heme_msk_impact_2022", "source_version": null, "retrieved_at": "2026-09-26", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: MSK-IMPACT Heme, follicular lymphoma subset (2022), 13/193 patients (6.74%).", "Observed in 1 of 1 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "heme_msk_impact_2022", "cohort_name": "MSK-IMPACT Heme, follicular lymphoma subset (2022)", "altered": 13, "tested": 193, "frequency": 6.74, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "213/2383", "coverage_note": null, "source_id": "heme_msk_impact_2022", "is_reference": true}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 22.47, "width": 1.0, "reference": 22.47, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 13, "tested": 193, "frequency": 6.74, "is_mutation": true}, "fda_badge": null, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "H1-2", "alteration_types": ["SNV / small indel"], "altered": 13, "tested": 193, "frequency": 6.74, "cohort_count": 1, "frequency_range": {"min": 6.74, "max": 6.74}, "major_variants": ["A61T (n=2)", "A171P (n=2)", "A190T (n=1)", "S78Rfs*2 (n=1)", "A101S (n=1)"], "evidence_confidence": "low", "disease_relevance": "Among the most frequently mutated genes in the reference cohort.", "targetability": "Not an FDA-recognised biomarker of drug response as of November 2022. This is not a statement that the gene is undruggable: levels 2 to 4 and non-US approvals are outside this table.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry.", "FDA biomarker status is level 1 only, United States only, and frozen at November 2022; no badge does not mean not druggable."], "sources": [{"source_name": "cBioPortal · MSK-IMPACT Heme, follicular lymphoma subset (2022)", "source_url": "https://www.cbioportal.org/study/summary?id=heme_msk_impact_2022", "source_record_id": "heme_msk_impact_2022", "source_version": null, "retrieved_at": "2026-09-26", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: MSK-IMPACT Heme, follicular lymphoma subset (2022), 13/193 patients (6.74%).", "Observed in 1 of 1 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "heme_msk_impact_2022", "cohort_name": "MSK-IMPACT Heme, follicular lymphoma subset (2022)", "altered": 13, "tested": 193, "frequency": 6.74, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "213/2383", "coverage_note": null, "source_id": "heme_msk_impact_2022", "is_reference": true}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 22.47, "width": 1.0, "reference": 22.47, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 13, "tested": 193, "frequency": 6.74, "is_mutation": true}, "fda_badge": null, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "LTB", "alteration_types": ["SNV / small indel", "amplification", "deep deletion"], "altered": 12, "tested": 193, "frequency": 6.22, "cohort_count": 1, "frequency_range": {"min": 6.22, "max": 6.22}, "major_variants": ["L46* (n=2)", "V36L (n=2)", "L74* (n=1)", "X55_splice (n=1)", "P48A (n=1)"], "evidence_confidence": "low", "disease_relevance": "Among the most frequently mutated genes in the reference cohort.", "targetability": "Not an FDA-recognised biomarker of drug response as of November 2022. This is not a statement that the gene is undruggable: levels 2 to 4 and non-US approvals are outside this table.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry.", "FDA biomarker status is level 1 only, United States only, and frozen at November 2022; no badge does not mean not druggable."], "sources": [{"source_name": "cBioPortal · MSK-IMPACT Heme, follicular lymphoma subset (2022)", "source_url": "https://www.cbioportal.org/study/summary?id=heme_msk_impact_2022", "source_record_id": "heme_msk_impact_2022", "source_version": null, "retrieved_at": "2026-09-26", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: MSK-IMPACT Heme, follicular lymphoma subset (2022), 12/193 patients (6.22%).", "Observed in 1 of 1 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "heme_msk_impact_2022", "cohort_name": "MSK-IMPACT Heme, follicular lymphoma subset (2022)", "altered": 12, "tested": 193, "frequency": 6.22, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "213/2383", "coverage_note": null, "source_id": "heme_msk_impact_2022", "is_reference": true}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 20.73, "width": 1.0, "reference": 20.73, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 12, "tested": 193, "frequency": 6.22, "is_mutation": true}, "fda_badge": null, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "CCND3", "alteration_types": ["SNV / small indel"], "altered": 12, "tested": 193, "frequency": 6.22, "cohort_count": 1, "frequency_range": {"min": 6.22, "max": 6.22}, "major_variants": ["I290K (n=3)", "R271Pfs*53 (n=2)", "P284R (n=1)", "I290R (n=1)", "I290T (n=1)"], "evidence_confidence": "low", "disease_relevance": "Among the most frequently mutated genes in the reference cohort.", "targetability": "Not an FDA-recognised biomarker of drug response as of November 2022. This is not a statement that the gene is undruggable: levels 2 to 4 and non-US approvals are outside this table.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry.", "FDA biomarker status is level 1 only, United States only, and frozen at November 2022; no badge does not mean not druggable."], "sources": [{"source_name": "cBioPortal · MSK-IMPACT Heme, follicular lymphoma subset (2022)", "source_url": "https://www.cbioportal.org/study/summary?id=heme_msk_impact_2022", "source_record_id": "heme_msk_impact_2022", "source_version": null, "retrieved_at": "2026-09-26", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: MSK-IMPACT Heme, follicular lymphoma subset (2022), 12/193 patients (6.22%).", "Observed in 1 of 1 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "heme_msk_impact_2022", "cohort_name": "MSK-IMPACT Heme, follicular lymphoma subset (2022)", "altered": 12, "tested": 193, "frequency": 6.22, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "213/2383", "coverage_note": null, "source_id": "heme_msk_impact_2022", "is_reference": true}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 20.73, "width": 1.0, "reference": 20.73, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 12, "tested": 193, "frequency": 6.22, "is_mutation": true}, "fda_badge": null, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "B2M", "alteration_types": ["SNV / small indel", "deep deletion"], "altered": 12, "tested": 193, "frequency": 6.22, "cohort_count": 1, "frequency_range": {"min": 6.22, "max": 6.22}, "major_variants": ["M1? (n=8)", "L12P (n=2)", "L43P (n=1)", "R3Lfs*55 (n=1)", "X23_splice (n=1)"], "evidence_confidence": "low", "disease_relevance": "Among the most frequently mutated genes in the reference cohort.", "targetability": "Not an FDA-recognised biomarker of drug response as of November 2022. This is not a statement that the gene is undruggable: levels 2 to 4 and non-US approvals are outside this table.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry.", "FDA biomarker status is level 1 only, United States only, and frozen at November 2022; no badge does not mean not druggable."], "sources": [{"source_name": "cBioPortal · MSK-IMPACT Heme, follicular lymphoma subset (2022)", "source_url": "https://www.cbioportal.org/study/summary?id=heme_msk_impact_2022", "source_record_id": "heme_msk_impact_2022", "source_version": null, "retrieved_at": "2026-09-26", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: MSK-IMPACT Heme, follicular lymphoma subset (2022), 12/193 patients (6.22%).", "Observed in 1 of 1 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "heme_msk_impact_2022", "cohort_name": "MSK-IMPACT Heme, follicular lymphoma subset (2022)", "altered": 12, "tested": 193, "frequency": 6.22, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "213/2383", "coverage_note": null, "source_id": "heme_msk_impact_2022", "is_reference": true}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 20.73, "width": 1.0, "reference": 20.73, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 12, "tested": 193, "frequency": 6.22, "is_mutation": true}, "fda_badge": null, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "ACTG1", "alteration_types": ["SNV / small indel"], "altered": 12, "tested": 193, "frequency": 6.22, "cohort_count": 1, "frequency_range": {"min": 6.22, "max": 6.22}, "major_variants": ["S60R (n=3)", "G13D (n=2)", "I10T (n=2)", "G20D (n=1)", "H73N (n=1)"], "evidence_confidence": "low", "disease_relevance": "Among the most frequently mutated genes in the reference cohort.", "targetability": "Not an FDA-recognised biomarker of drug response as of November 2022. This is not a statement that the gene is undruggable: levels 2 to 4 and non-US approvals are outside this table.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry.", "FDA biomarker status is level 1 only, United States only, and frozen at November 2022; no badge does not mean not druggable."], "sources": [{"source_name": "cBioPortal · MSK-IMPACT Heme, follicular lymphoma subset (2022)", "source_url": "https://www.cbioportal.org/study/summary?id=heme_msk_impact_2022", "source_record_id": "heme_msk_impact_2022", "source_version": null, "retrieved_at": "2026-09-26", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: MSK-IMPACT Heme, follicular lymphoma subset (2022), 12/193 patients (6.22%).", "Observed in 1 of 1 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "heme_msk_impact_2022", "cohort_name": "MSK-IMPACT Heme, follicular lymphoma subset (2022)", "altered": 12, "tested": 193, "frequency": 6.22, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "213/2383", "coverage_note": null, "source_id": "heme_msk_impact_2022", "is_reference": true}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 20.73, "width": 1.0, "reference": 20.73, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 12, "tested": 193, "frequency": 6.22, "is_mutation": true}, "fda_badge": null, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "FAT1", "alteration_types": ["SNV / small indel", "amplification", "deep deletion"], "altered": 11, "tested": 193, "frequency": 5.7, "cohort_count": 1, "frequency_range": {"min": 5.7, "max": 5.7}, "major_variants": ["P4258L (n=1)", "K2692E (n=1)", "V3318I (n=1)", "R1543P (n=1)", "V2214G (n=1)"], "evidence_confidence": "low", "disease_relevance": "Among the most frequently mutated genes in the reference cohort.", "targetability": "Not an FDA-recognised biomarker of drug response as of November 2022. This is not a statement that the gene is undruggable: levels 2 to 4 and non-US approvals are outside this table.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry.", "FDA biomarker status is level 1 only, United States only, and frozen at November 2022; no badge does not mean not druggable."], "sources": [{"source_name": "cBioPortal · MSK-IMPACT Heme, follicular lymphoma subset (2022)", "source_url": "https://www.cbioportal.org/study/summary?id=heme_msk_impact_2022", "source_record_id": "heme_msk_impact_2022", "source_version": null, "retrieved_at": "2026-09-26", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: MSK-IMPACT Heme, follicular lymphoma subset (2022), 11/193 patients (5.7%).", "Observed in 1 of 1 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "heme_msk_impact_2022", "cohort_name": "MSK-IMPACT Heme, follicular lymphoma subset (2022)", "altered": 11, "tested": 193, "frequency": 5.7, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "213/2383", "coverage_note": null, "source_id": "heme_msk_impact_2022", "is_reference": true}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 19.0, "width": 1.0, "reference": 19.0, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 11, "tested": 193, "frequency": 5.7, "is_mutation": true}, "fda_badge": null, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "FAS", "alteration_types": ["SNV / small indel", "deep deletion"], "altered": 11, "tested": 193, "frequency": 5.7, "cohort_count": 1, "frequency_range": {"min": 5.7, "max": 5.7}, "major_variants": ["G286E (n=2)", "M1? (n=2)", "X218_splice (n=1)", "K246* (n=1)", "Q26* (n=1)"], "evidence_confidence": "low", "disease_relevance": "Among the most frequently mutated genes in the reference cohort.", "targetability": "Not an FDA-recognised biomarker of drug response as of November 2022. This is not a statement that the gene is undruggable: levels 2 to 4 and non-US approvals are outside this table.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry.", "FDA biomarker status is level 1 only, United States only, and frozen at November 2022; no badge does not mean not druggable."], "sources": [{"source_name": "cBioPortal · MSK-IMPACT Heme, follicular lymphoma subset (2022)", "source_url": "https://www.cbioportal.org/study/summary?id=heme_msk_impact_2022", "source_record_id": "heme_msk_impact_2022", "source_version": null, "retrieved_at": "2026-09-26", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: MSK-IMPACT Heme, follicular lymphoma subset (2022), 11/193 patients (5.7%).", "Observed in 1 of 1 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "heme_msk_impact_2022", "cohort_name": "MSK-IMPACT Heme, follicular lymphoma subset (2022)", "altered": 11, "tested": 193, "frequency": 5.7, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "213/2383", "coverage_note": null, "source_id": "heme_msk_impact_2022", "is_reference": true}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 19.0, "width": 1.0, "reference": 19.0, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 11, "tested": 193, "frequency": 5.7, "is_mutation": true}, "fda_badge": null, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "DTX1", "alteration_types": ["SNV / small indel"], "altered": 10, "tested": 193, "frequency": 5.18, "cohort_count": 1, "frequency_range": {"min": 5.18, "max": 5.18}, "major_variants": ["Q81R (n=2)", "G58D (n=2)", "V70L (n=2)", "N21I (n=1)", "*35* (n=1)"], "evidence_confidence": "low", "disease_relevance": "Among the most frequently mutated genes in the reference cohort.", "targetability": "Not an FDA-recognised biomarker of drug response as of November 2022. This is not a statement that the gene is undruggable: levels 2 to 4 and non-US approvals are outside this table.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry.", "FDA biomarker status is level 1 only, United States only, and frozen at November 2022; no badge does not mean not druggable."], "sources": [{"source_name": "cBioPortal · MSK-IMPACT Heme, follicular lymphoma subset (2022)", "source_url": "https://www.cbioportal.org/study/summary?id=heme_msk_impact_2022", "source_record_id": "heme_msk_impact_2022", "source_version": null, "retrieved_at": "2026-09-26", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: MSK-IMPACT Heme, follicular lymphoma subset (2022), 10/193 patients (5.18%).", "Observed in 1 of 1 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "heme_msk_impact_2022", "cohort_name": "MSK-IMPACT Heme, follicular lymphoma subset (2022)", "altered": 10, "tested": 193, "frequency": 5.18, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "213/2383", "coverage_note": null, "source_id": "heme_msk_impact_2022", "is_reference": true}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 17.27, "width": 1.0, "reference": 17.27, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 10, "tested": 193, "frequency": 5.18, "is_mutation": true}, "fda_badge": null, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "BTG1", "alteration_types": ["SNV / small indel"], "altered": 9, "tested": 193, "frequency": 4.66, "cohort_count": 1, "frequency_range": {"min": 4.66, "max": 4.66}, "major_variants": ["L37M (n=2)", "S43N (n=2)", "F25S (n=1)", "L37Q (n=1)", "Q36H (n=1)"], "evidence_confidence": "low", "disease_relevance": "Among the most frequently mutated genes in the reference cohort.", "targetability": "Not an FDA-recognised biomarker of drug response as of November 2022. This is not a statement that the gene is undruggable: levels 2 to 4 and non-US approvals are outside this table.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry.", "FDA biomarker status is level 1 only, United States only, and frozen at November 2022; no badge does not mean not druggable."], "sources": [{"source_name": "cBioPortal · MSK-IMPACT Heme, follicular lymphoma subset (2022)", "source_url": "https://www.cbioportal.org/study/summary?id=heme_msk_impact_2022", "source_record_id": "heme_msk_impact_2022", "source_version": null, "retrieved_at": "2026-09-26", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: MSK-IMPACT Heme, follicular lymphoma subset (2022), 9/193 patients (4.66%).", "Observed in 1 of 1 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "heme_msk_impact_2022", "cohort_name": "MSK-IMPACT Heme, follicular lymphoma subset (2022)", "altered": 9, "tested": 193, "frequency": 4.66, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "213/2383", "coverage_note": null, "source_id": "heme_msk_impact_2022", "is_reference": true}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 15.53, "width": 1.0, "reference": 15.53, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 9, "tested": 193, "frequency": 4.66, "is_mutation": true}, "fda_badge": null, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "HLA-A", "alteration_types": ["SNV / small indel"], "altered": 8, "tested": 193, "frequency": 4.15, "cohort_count": 1, "frequency_range": {"min": 4.15, "max": 4.15}, "major_variants": ["Q78* (n=2)", "L12Hfs*82 (n=1)", "Y31* (n=1)", "L150Q (n=1)", "L13Pfs*82 (n=1)"], "evidence_confidence": "low", "disease_relevance": "Among the most frequently mutated genes in the reference cohort.", "targetability": "Not an FDA-recognised biomarker of drug response as of November 2022. This is not a statement that the gene is undruggable: levels 2 to 4 and non-US approvals are outside this table.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry.", "FDA biomarker status is level 1 only, United States only, and frozen at November 2022; no badge does not mean not druggable."], "sources": [{"source_name": "cBioPortal · MSK-IMPACT Heme, follicular lymphoma subset (2022)", "source_url": "https://www.cbioportal.org/study/summary?id=heme_msk_impact_2022", "source_record_id": "heme_msk_impact_2022", "source_version": null, "retrieved_at": "2026-09-26", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: MSK-IMPACT Heme, follicular lymphoma subset (2022), 8/193 patients (4.15%).", "Observed in 1 of 1 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "heme_msk_impact_2022", "cohort_name": "MSK-IMPACT Heme, follicular lymphoma subset (2022)", "altered": 8, "tested": 193, "frequency": 4.15, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "213/2383", "coverage_note": null, "source_id": "heme_msk_impact_2022", "is_reference": true}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 13.83, "width": 1.0, "reference": 13.83, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 8, "tested": 193, "frequency": 4.15, "is_mutation": true}, "fda_badge": null, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "H1-5", "alteration_types": ["SNV / small indel"], "altered": 8, "tested": 193, "frequency": 4.15, "cohort_count": 1, "frequency_range": {"min": 4.15, "max": 4.15}, "major_variants": ["P203S (n=2)", "S92N (n=2)", "K172T (n=1)", "A131G (n=1)", "A177T (n=1)"], "evidence_confidence": "low", "disease_relevance": "Among the most frequently mutated genes in the reference cohort.", "targetability": "Not an FDA-recognised biomarker of drug response as of November 2022. This is not a statement that the gene is undruggable: levels 2 to 4 and non-US approvals are outside this table.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry.", "FDA biomarker status is level 1 only, United States only, and frozen at November 2022; no badge does not mean not druggable."], "sources": [{"source_name": "cBioPortal · MSK-IMPACT Heme, follicular lymphoma subset (2022)", "source_url": "https://www.cbioportal.org/study/summary?id=heme_msk_impact_2022", "source_record_id": "heme_msk_impact_2022", "source_version": null, "retrieved_at": "2026-09-26", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: MSK-IMPACT Heme, follicular lymphoma subset (2022), 8/193 patients (4.15%).", "Observed in 1 of 1 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "heme_msk_impact_2022", "cohort_name": "MSK-IMPACT Heme, follicular lymphoma subset (2022)", "altered": 8, "tested": 193, "frequency": 4.15, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "213/2383", "coverage_note": null, "source_id": "heme_msk_impact_2022", "is_reference": true}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 13.83, "width": 1.0, "reference": 13.83, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 8, "tested": 193, "frequency": 4.15, "is_mutation": true}, "fda_badge": null, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "H1-3", "alteration_types": ["SNV / small indel"], "altered": 8, "tested": 193, "frequency": 4.15, "cohort_count": 1, "frequency_range": {"min": 4.15, "max": 4.15}, "major_variants": ["A102T (n=1)", "K131R (n=1)", "G92D (n=1)", "A191T (n=1)", "S87N (n=1)"], "evidence_confidence": "low", "disease_relevance": "Among the most frequently mutated genes in the reference cohort.", "targetability": "Not an FDA-recognised biomarker of drug response as of November 2022. This is not a statement that the gene is undruggable: levels 2 to 4 and non-US approvals are outside this table.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry.", "FDA biomarker status is level 1 only, United States only, and frozen at November 2022; no badge does not mean not druggable."], "sources": [{"source_name": "cBioPortal · MSK-IMPACT Heme, follicular lymphoma subset (2022)", "source_url": "https://www.cbioportal.org/study/summary?id=heme_msk_impact_2022", "source_record_id": "heme_msk_impact_2022", "source_version": null, "retrieved_at": "2026-09-26", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: MSK-IMPACT Heme, follicular lymphoma subset (2022), 8/193 patients (4.15%).", "Observed in 1 of 1 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "heme_msk_impact_2022", "cohort_name": "MSK-IMPACT Heme, follicular lymphoma subset (2022)", "altered": 8, "tested": 193, "frequency": 4.15, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "213/2383", "coverage_note": null, "source_id": "heme_msk_impact_2022", "is_reference": true}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 13.83, "width": 1.0, "reference": 13.83, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 8, "tested": 193, "frequency": 4.15, "is_mutation": true}, "fda_badge": null, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "EPHA5", "alteration_types": ["SNV / small indel"], "altered": 8, "tested": 193, "frequency": 4.15, "cohort_count": 1, "frequency_range": {"min": 4.15, "max": 4.15}, "major_variants": ["T944M (n=1)", "C408R (n=1)", "A831S (n=1)", "A890V (n=1)", "P697Q (n=1)"], "evidence_confidence": "low", "disease_relevance": "Among the most frequently mutated genes in the reference cohort.", "targetability": "Not an FDA-recognised biomarker of drug response as of November 2022. This is not a statement that the gene is undruggable: levels 2 to 4 and non-US approvals are outside this table.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry.", "FDA biomarker status is level 1 only, United States only, and frozen at November 2022; no badge does not mean not druggable."], "sources": [{"source_name": "cBioPortal · MSK-IMPACT Heme, follicular lymphoma subset (2022)", "source_url": "https://www.cbioportal.org/study/summary?id=heme_msk_impact_2022", "source_record_id": "heme_msk_impact_2022", "source_version": null, "retrieved_at": "2026-09-26", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: MSK-IMPACT Heme, follicular lymphoma subset (2022), 8/193 patients (4.15%).", "Observed in 1 of 1 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "heme_msk_impact_2022", "cohort_name": "MSK-IMPACT Heme, follicular lymphoma subset (2022)", "altered": 8, "tested": 193, "frequency": 4.15, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "213/2383", "coverage_note": null, "source_id": "heme_msk_impact_2022", "is_reference": true}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 13.83, "width": 1.0, "reference": 13.83, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 8, "tested": 193, "frequency": 4.15, "is_mutation": true}, "fda_badge": null, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "ATP6AP1", "alteration_types": ["SNV / small indel"], "altered": 7, "tested": 193, "frequency": 3.63, "cohort_count": 1, "frequency_range": {"min": 3.63, "max": 3.63}, "major_variants": ["E346K (n=1)", "D284G (n=1)", "S335F (n=1)", "S305F (n=1)", "A3Rfs*76 (n=1)"], "evidence_confidence": "low", "disease_relevance": "Among the most frequently mutated genes in the reference cohort.", "targetability": "Not an FDA-recognised biomarker of drug response as of November 2022. This is not a statement that the gene is undruggable: levels 2 to 4 and non-US approvals are outside this table.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry.", "FDA biomarker status is level 1 only, United States only, and frozen at November 2022; no badge does not mean not druggable."], "sources": [{"source_name": "cBioPortal · MSK-IMPACT Heme, follicular lymphoma subset (2022)", "source_url": "https://www.cbioportal.org/study/summary?id=heme_msk_impact_2022", "source_record_id": "heme_msk_impact_2022", "source_version": null, "retrieved_at": "2026-09-26", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: MSK-IMPACT Heme, follicular lymphoma subset (2022), 7/193 patients (3.63%).", "Observed in 1 of 1 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "heme_msk_impact_2022", "cohort_name": "MSK-IMPACT Heme, follicular lymphoma subset (2022)", "altered": 7, "tested": 193, "frequency": 3.63, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "213/2383", "coverage_note": null, "source_id": "heme_msk_impact_2022", "is_reference": true}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 12.1, "width": 1.0, "reference": 12.1, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 7, "tested": 193, "frequency": 3.63, "is_mutation": true}, "fda_badge": null, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "ARID5B", "alteration_types": ["SNV / small indel"], "altered": 7, "tested": 193, "frequency": 3.63, "cohort_count": 1, "frequency_range": {"min": 3.63, "max": 3.63}, "major_variants": ["F21L (n=1)", "S588Vfs*41 (n=1)", "S71F (n=1)", "W61* (n=1)", "X467_splice (n=1)"], "evidence_confidence": "low", "disease_relevance": "Among the most frequently mutated genes in the reference cohort.", "targetability": "Not an FDA-recognised biomarker of drug response as of November 2022. This is not a statement that the gene is undruggable: levels 2 to 4 and non-US approvals are outside this table.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry.", "FDA biomarker status is level 1 only, United States only, and frozen at November 2022; no badge does not mean not druggable."], "sources": [{"source_name": "cBioPortal · MSK-IMPACT Heme, follicular lymphoma subset (2022)", "source_url": "https://www.cbioportal.org/study/summary?id=heme_msk_impact_2022", "source_record_id": "heme_msk_impact_2022", "source_version": null, "retrieved_at": "2026-09-26", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: MSK-IMPACT Heme, follicular lymphoma subset (2022), 7/193 patients (3.63%).", "Observed in 1 of 1 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "heme_msk_impact_2022", "cohort_name": "MSK-IMPACT Heme, follicular lymphoma subset (2022)", "altered": 7, "tested": 193, "frequency": 3.63, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "213/2383", "coverage_note": null, "source_id": "heme_msk_impact_2022", "is_reference": true}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 12.1, "width": 1.0, "reference": 12.1, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 7, "tested": 193, "frequency": 3.63, "is_mutation": true}, "fda_badge": null, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}], "variants": [], "genomic_events": [{"event_type": "copy_number", "gene": "TNFRSF14", "denominator_note": "Patients in the cohort's copy-number sample list.", "partner_gene": null, "alteration": "deep deletion", "event_label": "TNFRSF14 deep deletion", "genomic_coordinate": null, "observed": 22, "observed_status": "observed", "observed_unit": "patients", "tested": 193, "tested_status": "observed", "tested_unit": "patients", "frequency": 11.4, "frequency_status": "observed", "frequency_unit": "percent", "cohorts": ["heme_msk_impact_2022"], "source_ids": ["heme_msk_impact_2022_cna"], "evidence_confidence": "moderate", "details": null}, {"event_type": "copy_number", "gene": "TNFAIP3", "denominator_note": "Patients in the cohort's copy-number sample list.", "partner_gene": null, "alteration": "deep deletion", "event_label": "TNFAIP3 deep deletion", "genomic_coordinate": null, "observed": 10, "observed_status": "observed", "observed_unit": "patients", "tested": 193, "tested_status": "observed", "tested_unit": "patients", "frequency": 5.18, "frequency_status": "observed", "frequency_unit": "percent", "cohorts": ["heme_msk_impact_2022"], "source_ids": ["heme_msk_impact_2022_cna"], "evidence_confidence": "moderate", "details": null}, {"event_type": "copy_number", "gene": "FAS", "denominator_note": "Patients in the cohort's copy-number sample list.", "partner_gene": null, "alteration": "deep deletion", "event_label": "FAS deep deletion", "genomic_coordinate": null, "observed": 6, "observed_status": "observed", "observed_unit": "patients", "tested": 193, "tested_status": "observed", "tested_unit": "patients", "frequency": 3.11, "frequency_status": "observed", "frequency_unit": "percent", "cohorts": ["heme_msk_impact_2022"], "source_ids": ["heme_msk_impact_2022_cna"], "evidence_confidence": "moderate", "details": null}, {"event_type": "copy_number", "gene": "CREBBP", "denominator_note": "Patients in the cohort's copy-number sample list.", "partner_gene": null, "alteration": "deep deletion", "event_label": "CREBBP deep deletion", "genomic_coordinate": null, "observed": 4, "observed_status": "observed", "observed_unit": "patients", "tested": 193, "tested_status": "observed", "tested_unit": "patients", "frequency": 2.07, "frequency_status": "observed", "frequency_unit": "percent", "cohorts": ["heme_msk_impact_2022"], "source_ids": ["heme_msk_impact_2022_cna"], "evidence_confidence": "moderate", "details": null}, {"event_type": "copy_number", "gene": "SOCS1", "denominator_note": "Patients in the cohort's copy-number sample list.", "partner_gene": null, "alteration": "deep deletion", "event_label": "SOCS1 deep deletion", "genomic_coordinate": null, "observed": 4, "observed_status": "observed", "observed_unit": "patients", "tested": 193, "tested_status": "observed", "tested_unit": "patients", "frequency": 2.07, "frequency_status": "observed", "frequency_unit": "percent", "cohorts": ["heme_msk_impact_2022"], "source_ids": ["heme_msk_impact_2022_cna"], "evidence_confidence": "moderate", "details": null}], "modality_summary": [{"modality": "SNV / small indel", "available_cohorts": 1, "total_cohorts": 1}, {"modality": "Copy number (discrete)", "available_cohorts": 1, "total_cohorts": 1}, {"modality": "Structural variant (present, not read)", "available_cohorts": 0, "total_cohorts": 1}], "chromosome_summary": [], "cohorts": [{"name": "MSK-IMPACT Heme, follicular lymphoma subset (2022)", "source": "cBioPortal", "accession": "heme_msk_impact_2022", "patients": {"value": 193, "status": "observed", "unit": "patients"}, "samples": {"value": 213, "status": "observed", "unit": "samples"}, "disease_subtype": "MSK-IMPACT Heme Tumors (MSK, 2022)", "assay_type": "targeted panel", "sequencing_method": "IMPACT-HEME-400 (213)", "genome_build": "hg19", "alteration_types_available": ["SNV", "small indel", "amplification", "deep deletion"], "genes_assayed": "panel genes only; per-gene denominators", "primary_or_metastatic": null, "age_group": null, "retrieved_at": "2026-09-26", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "source_record_id": "heme_msk_impact_2022", "is_demo": false, "assay_coverage": {"patients_with_calls": 193, "patients_in_roster": 193, "frequencies_computed": true, "samples_sequenced": 213, "samples_in_study": 2383, "hypermutated_patients": 0, "median_mutations_per_sample": 9, "reason": null}}], "sources": [{"source_name": "cBioPortal · MSK-IMPACT Heme, follicular lymphoma subset (2022)", "source_url": "https://www.cbioportal.org/study/summary?id=heme_msk_impact_2022", "source_record_id": "heme_msk_impact_2022", "source_version": null, "retrieved_at": "2026-09-26", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "limitations": ["A cBioPortal public-API snapshot retrieved 2026-09-26; the page does not refresh source data at request time.", "Counts are patients with at least one non-silent call in the study's sequenced sample list; silent, intronic and UTR calls are excluded.", "For targeted-panel cohorts each gene divides by the patients whose panel carried it; a gene absent from the panel is shown as not assayed, not as zero.", "Copy-number rows use discrete calls (2 = high-level amplification, −2 = deep deletion) against the cohort's copy-number sample list, which is a different roster from the sequenced one.", "Cohorts are not pooled. Cross-study patient overlap has not been checked and no disease-wide frequency is reported.", "Structural variants and fusions are not read in this snapshot even where the study carries a profile; germline variants, mutational signatures, TMB and MSI are not reported.", "The gene set is the briefing's curated targets plus the reference cohort's most frequently mutated genes; it is not genome-wide."], "answer_block": ["In MSK-IMPACT Heme, follicular lymphoma subset (2022) (193 sequenced patients, targeted panel), the most frequently altered of the 45 genes shown are CREBBP 70.98%, KMT2D 66.32%, TNFRSF14 46.63%, BCL2 34.72%, EZH2 20.73%. Each figure divides by the patients on whom that gene could be called.", "Of the briefing's 12 curated targets, 1 are altered in under 2% of this cohort (CD79B): targets by expression, dependency or drug label, not by mutation. Frequency is not targetability, in either direction.", "1 cohorts are shown and none are pooled; overlap between them has not been checked and there is no disease-wide percentage."], "key_findings": [{"finding": "CREBBP is mutated in 137 of 193 patients in MSK-IMPACT Heme, follicular lymphoma subset (2022).", "numerator": 137, "denominator": 193, "frequency": 70.98, "cohorts": 1, "evidence_confidence": "low", "source": "heme_msk_impact_2022", "retrieved_at": "2026-09-26"}, {"finding": "KMT2D is mutated in 128 of 193 patients in MSK-IMPACT Heme, follicular lymphoma subset (2022).", "numerator": 128, "denominator": 193, "frequency": 66.32, "cohorts": 1, "evidence_confidence": "low", "source": "heme_msk_impact_2022", "retrieved_at": "2026-09-26"}, {"finding": "TNFRSF14 is mutated in 90 of 193 patients in MSK-IMPACT Heme, follicular lymphoma subset (2022).", "numerator": 90, "denominator": 193, "frequency": 46.63, "cohorts": 1, "evidence_confidence": "low", "source": "heme_msk_impact_2022", "retrieved_at": "2026-09-26"}], "research_gaps": [{"kind": "Structural variants", "text": "Read the structural-variant profiles the studies carry; fusions are the defining event in several of these diseases."}, {"kind": "Context", "text": "Stage, subtype, age and treatment line are not attached to any count; the cohorts differ on all four."}, {"kind": "Interpretation", "text": "Activating versus inactivating, actionable versus not, and evidence level are not inferred here; the briefing's target table carries the drug and trial facts."}], "observations": [], "data_status": "PUBLIC SOURCE SNAPSHOT", "is_demo": false, "reference_cohort": "heme_msk_impact_2022", "region_events": [], "matrix": [{"label": "BCL2", "kind": "SNV / small indel", "gene": "BCL2", "cells": [{"cohort": "heme_msk_impact_2022", "status": "observed", "frequency": 34.72, "altered": 67, "tested": 193, "note": null}]}, {"label": "MS4A1", "kind": "SNV / small indel", "gene": "MS4A1", "cells": [{"cohort": "heme_msk_impact_2022", "status": "not_assayed", "frequency": null, "altered": null, "tested": null, "note": "Not on this cohort's gene panel."}]}, {"label": "CD19", "kind": "SNV / small indel", "gene": "CD19", "cells": [{"cohort": "heme_msk_impact_2022", "status": "not_assayed", "frequency": null, "altered": null, "tested": null, "note": "Not on this cohort's gene panel."}]}, {"label": "EZH2", "kind": "SNV / small indel", "gene": "EZH2", "cells": [{"cohort": "heme_msk_impact_2022", "status": "observed", "frequency": 20.73, "altered": 40, "tested": 193, "note": null}]}, {"label": "CREBBP", "kind": "SNV / small indel", "gene": "CREBBP", "cells": [{"cohort": "heme_msk_impact_2022", "status": "observed", "frequency": 70.98, "altered": 137, "tested": 193, "note": null}]}, {"label": "CREBBP", "kind": "deep deletion", "gene": "CREBBP", "cells": [{"cohort": "heme_msk_impact_2022", "status": "observed", "frequency": 2.07, "altered": 4, "tested": 193, "note": "Discrete copy-number call; divides by the cohort's copy-number roster."}]}, {"label": "KMT2D", "kind": "SNV / small indel", "gene": "KMT2D", "cells": [{"cohort": "heme_msk_impact_2022", "status": "observed", "frequency": 66.32, "altered": 128, "tested": 193, "note": null}]}, {"label": "CD79B", "kind": "SNV / small indel", "gene": "CD79B", "cells": [{"cohort": "heme_msk_impact_2022", "status": "observed", "frequency": 1.55, "altered": 3, "tested": 193, "note": null}]}, {"label": "PIK3CD", "kind": "SNV / small indel", "gene": "PIK3CD", "cells": [{"cohort": "heme_msk_impact_2022", "status": "not_assayed", "frequency": null, "altered": null, "tested": null, "note": "Not on this cohort's gene panel."}]}, {"label": "BTK", "kind": "SNV / small indel", "gene": "BTK", "cells": [{"cohort": "heme_msk_impact_2022", "status": "observed", "frequency": 6.22, "altered": 12, "tested": 193, "note": null}]}, {"label": "CD22", "kind": "SNV / small indel", "gene": "CD22", "cells": [{"cohort": "heme_msk_impact_2022", "status": "not_assayed", "frequency": null, "altered": null, "tested": null, "note": "Not on this cohort's gene panel."}]}, {"label": "TNFRSF14", "kind": "SNV / small indel", "gene": "TNFRSF14", "cells": [{"cohort": "heme_msk_impact_2022", "status": "observed", "frequency": 46.63, "altered": 90, "tested": 193, "note": null}]}, {"label": "TNFRSF14", "kind": "deep deletion", "gene": "TNFRSF14", "cells": [{"cohort": "heme_msk_impact_2022", "status": "observed", "frequency": 11.4, "altered": 22, "tested": 193, "note": "Discrete copy-number call; divides by the cohort's copy-number roster."}]}, {"label": "STAT6", "kind": "SNV / small indel", "gene": "STAT6", "cells": [{"cohort": "heme_msk_impact_2022", "status": "observed", "frequency": 20.21, "altered": 39, "tested": 193, "note": null}]}, {"label": "FOXO1", "kind": "SNV / small indel", "gene": "FOXO1", "cells": [{"cohort": "heme_msk_impact_2022", "status": "observed", "frequency": 18.13, "altered": 35, "tested": 193, "note": null}]}, {"label": "SOCS1", "kind": "SNV / small indel", "gene": "SOCS1", "cells": [{"cohort": "heme_msk_impact_2022", "status": "observed", "frequency": 15.54, "altered": 30, "tested": 193, "note": null}]}, {"label": "SOCS1", "kind": "deep deletion", "gene": "SOCS1", "cells": [{"cohort": "heme_msk_impact_2022", "status": "observed", "frequency": 2.07, "altered": 4, "tested": 193, "note": "Discrete copy-number call; divides by the cohort's copy-number roster."}]}, {"label": "H1-4", "kind": "SNV / small indel", "gene": "H1-4", "cells": [{"cohort": "heme_msk_impact_2022", "status": "observed", "frequency": 15.54, "altered": 30, "tested": 193, "note": null}]}, {"label": "IRF8", "kind": "SNV / small indel", "gene": "IRF8", "cells": [{"cohort": "heme_msk_impact_2022", "status": "observed", "frequency": 15.03, "altered": 29, "tested": 193, "note": null}]}, {"label": "ARID1A", "kind": "SNV / small indel", "gene": "ARID1A", "cells": [{"cohort": "heme_msk_impact_2022", "status": "observed", "frequency": 13.47, "altered": 26, "tested": 193, "note": null}]}, {"label": "MEF2B", "kind": "SNV / small indel", "gene": "MEF2B", "cells": [{"cohort": "heme_msk_impact_2022", "status": "observed", "frequency": 11.92, "altered": 23, "tested": 193, "note": null}]}, {"label": "EP300", "kind": "SNV / small indel", "gene": "EP300", "cells": [{"cohort": "heme_msk_impact_2022", "status": "observed", "frequency": 10.88, "altered": 21, "tested": 193, "note": null}]}, {"label": "CARD11", "kind": "SNV / small indel", "gene": "CARD11", "cells": [{"cohort": "heme_msk_impact_2022", "status": "observed", "frequency": 10.88, "altered": 21, "tested": 193, "note": null}]}, {"label": "TNFAIP3", "kind": "SNV / small indel", "gene": "TNFAIP3", "cells": [{"cohort": "heme_msk_impact_2022", "status": "observed", "frequency": 10.36, "altered": 20, "tested": 193, "note": null}]}, {"label": "TNFAIP3", "kind": "deep deletion", "gene": "TNFAIP3", "cells": [{"cohort": "heme_msk_impact_2022", "status": "observed", "frequency": 5.18, "altered": 10, "tested": 193, "note": "Discrete copy-number call; divides by the cohort's copy-number roster."}]}, {"label": "GNA13", "kind": "SNV / small indel", "gene": "GNA13", "cells": [{"cohort": "heme_msk_impact_2022", "status": "observed", "frequency": 9.84, "altered": 19, "tested": 193, "note": null}]}, {"label": "TP53", "kind": "SNV / small indel", "gene": "TP53", "cells": [{"cohort": "heme_msk_impact_2022", "status": "observed", "frequency": 9.33, "altered": 18, "tested": 193, "note": null}]}, {"label": "RRAGC", "kind": "SNV / small indel", "gene": "RRAGC", "cells": [{"cohort": "heme_msk_impact_2022", "status": "observed", "frequency": 9.33, "altered": 18, "tested": 193, "note": null}]}, {"label": "ATP6V1B2", "kind": "SNV / small indel", "gene": "ATP6V1B2", "cells": [{"cohort": "heme_msk_impact_2022", "status": "observed", "frequency": 8.29, "altered": 16, "tested": 193, "note": null}]}, {"label": "BCR", "kind": "SNV / small indel", "gene": "BCR", "cells": [{"cohort": "heme_msk_impact_2022", "status": "observed", "frequency": 7.77, "altered": 15, "tested": 193, "note": null}]}, {"label": "SGK1", "kind": "SNV / small indel", "gene": "SGK1", "cells": [{"cohort": "heme_msk_impact_2022", "status": "observed", "frequency": 7.25, "altered": 14, "tested": 193, "note": null}]}, {"label": "PIM1", "kind": "SNV / small indel", "gene": "PIM1", "cells": [{"cohort": "heme_msk_impact_2022", "status": "observed", "frequency": 7.25, "altered": 14, "tested": 193, "note": null}]}, {"label": "SRSF2", "kind": "SNV / small indel", "gene": "SRSF2", "cells": [{"cohort": "heme_msk_impact_2022", "status": "observed", "frequency": 6.74, "altered": 13, "tested": 193, "note": null}]}, {"label": "SETD1B", "kind": "SNV / small indel", "gene": "SETD1B", "cells": [{"cohort": "heme_msk_impact_2022", "status": "observed", "frequency": 6.74, "altered": 13, "tested": 193, "note": null}]}, {"label": "H1-2", "kind": "SNV / small indel", "gene": "H1-2", "cells": [{"cohort": "heme_msk_impact_2022", "status": "observed", "frequency": 6.74, "altered": 13, "tested": 193, "note": null}]}, {"label": "LTB", "kind": "SNV / small indel", "gene": "LTB", "cells": [{"cohort": "heme_msk_impact_2022", "status": "observed", "frequency": 6.22, "altered": 12, "tested": 193, "note": null}]}, {"label": "CCND3", "kind": "SNV / small indel", "gene": "CCND3", "cells": [{"cohort": "heme_msk_impact_2022", "status": "observed", "frequency": 6.22, "altered": 12, "tested": 193, "note": null}]}, {"label": "B2M", "kind": "SNV / small indel", "gene": "B2M", "cells": [{"cohort": "heme_msk_impact_2022", "status": "observed", "frequency": 6.22, "altered": 12, "tested": 193, "note": null}]}, {"label": "ACTG1", "kind": "SNV / small indel", "gene": "ACTG1", "cells": [{"cohort": "heme_msk_impact_2022", "status": "observed", "frequency": 6.22, "altered": 12, "tested": 193, "note": null}]}, {"label": "FAT1", "kind": "SNV / small indel", "gene": "FAT1", "cells": [{"cohort": "heme_msk_impact_2022", "status": "observed", "frequency": 5.7, "altered": 11, "tested": 193, "note": null}]}, {"label": "FAS", "kind": "SNV / small indel", "gene": "FAS", "cells": [{"cohort": "heme_msk_impact_2022", "status": "observed", "frequency": 5.7, "altered": 11, "tested": 193, "note": null}]}, {"label": "FAS", "kind": "deep deletion", "gene": "FAS", "cells": [{"cohort": "heme_msk_impact_2022", "status": "observed", "frequency": 3.11, "altered": 6, "tested": 193, "note": "Discrete copy-number call; divides by the cohort's copy-number roster."}]}, {"label": "DTX1", "kind": "SNV / small indel", "gene": "DTX1", "cells": [{"cohort": "heme_msk_impact_2022", "status": "observed", "frequency": 5.18, "altered": 10, "tested": 193, "note": null}]}, {"label": "BTG1", "kind": "SNV / small indel", "gene": "BTG1", "cells": [{"cohort": "heme_msk_impact_2022", "status": "observed", "frequency": 4.66, "altered": 9, "tested": 193, "note": null}]}, {"label": "HLA-A", "kind": "SNV / small indel", "gene": "HLA-A", "cells": [{"cohort": "heme_msk_impact_2022", "status": "observed", "frequency": 4.15, "altered": 8, "tested": 193, "note": null}]}, {"label": "H1-5", "kind": "SNV / small indel", "gene": "H1-5", "cells": [{"cohort": "heme_msk_impact_2022", "status": "observed", "frequency": 4.15, "altered": 8, "tested": 193, "note": null}]}, {"label": "H1-3", "kind": "SNV / small indel", "gene": "H1-3", "cells": [{"cohort": "heme_msk_impact_2022", "status": "observed", "frequency": 4.15, "altered": 8, "tested": 193, "note": null}]}, {"label": "EPHA5", "kind": "SNV / small indel", "gene": "EPHA5", "cells": [{"cohort": "heme_msk_impact_2022", "status": "observed", "frequency": 4.15, "altered": 8, "tested": 193, "note": null}]}, {"label": "ATP6AP1", "kind": "SNV / small indel", "gene": "ATP6AP1", "cells": [{"cohort": "heme_msk_impact_2022", "status": "observed", "frequency": 3.63, "altered": 7, "tested": 193, "note": null}]}, {"label": "ARID5B", "kind": "SNV / small indel", "gene": "ARID5B", "cells": [{"cohort": "heme_msk_impact_2022", "status": "observed", "frequency": 3.63, "altered": 7, "tested": 193, "note": null}]}]}